BL-ARC002
/ Sichuan Biokin Pharmaceutical
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
September 23, 2026
A Study of BL-ARC002 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
(clinicaltrials.gov)
- P1 | N=22 | Recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Colorectal Cancer • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor
August 14, 2026
A Study of BL-ARC002 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
(clinicaltrials.gov)
- P1 | N=22 | Not yet recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
New P1 trial • Colorectal Cancer • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor
May 29, 2026
A Study of BL-ARC002 in Patients With Locally Advanced or Metastatic Solid Tumors
(clinicaltrials.gov)
- P1 | N=22 | Recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Oncology • Solid Tumor
May 16, 2026
A Study of BL-ARC002 in Patients With Locally Advanced or Metastatic Solid Tumors
(clinicaltrials.gov)
- P1 | N=22 | Not yet recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
New P1 trial • Oncology • Solid Tumor
1 to 4
Of
4
Go to page
1